<unk>  , sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma. It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.<unk>  was approved for medical use in the United States in April 2021.
Loncastuximab tesirine
Polatuzumab vedotin
Margetuximab
Isatuximab
Moxetumomab pasudotox
Dinutuximab
Neratinib
Imatinib